Back

What is the evidence for SGLT2 inhibitors in HF?

26 August 2022 (15:40 - 15:50)
Organised by:
Congress Presentation Part of: SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022? Chronic Heart Failure, Other Open Access ESC Congress 2022

About the speaker

Photo
Professor Ileana Pina

Thomas Jefferson University, Philadelphia (United States of America)

3 More presentations in this session

Presentation thumbnail
Welcome and introduction.
Professor J. Butler (Dallas, US)
Slides Video
Presentation thumbnail
SGLT2 inhibitors for HF treatments in 2022 - What do the guidelines tell us?
Professor G. Rosano (London, GB)
Slides Video
Presentation thumbnail
Panel discussion.
Professor S. Anker (Berlin, DE)
Slides Video

Access the full session

Session thumbnail
SGLT2 inhibitors in practice (part 1): what is the state of heart failure treatment in 2022?
Video

The Event

Event poster

ESC Congress 2022

26 August 2022 15:40 CET
You may be interested in
thumbnail
Congress Session
SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?
27 August 2022
thumbnail
Congress Session
Overcoming clinical inertia in chronic heart failure care - SGLT2 inhibition across the spectrum of ejection fraction
20 May 2023
thumbnail
Congress Presentation
A patient with HF and LVEF > 40%: SGLT2 inhibitors.
27 August 2022
thumbnail
Congress Session
SGLT-2 inhibitors - Another piece of the puzzle in heart failure
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources